Plasma Fractionation Market Insights, 2018-2026
Global Plasma Fractionation Market - Snapshot
Plasma fractionation is the first process for large-scale protein purification, which was developed about 60 years ago by Cohn and co-workers. Currently, therapeutically important proteins are human serum albumin (HSA), immunoglobulin (IG), coagulation factor VIII, and protease inhibitors. Presently, plasma protein fractionation is, by far, the largest segment in the global therapeutic protein manufacture industry. Rising indications and therapeutic usage of plasma-derived proteins is an important factor that is expected to boost the plasma fractionation market during the forecast period. The global plasma fractionation market was valued at US$ 18,420.00 Mn in 2017 and is anticipated to reach US$ 33,763.10 Mn by 2026, expanding at a CAGR of 7.1% from 2018 to 2026. Rise in the geriatric population and the demand for plasma proteins is anticipated to drive the demand for plasma fractionation during the forecast period.
Increase in demand for plasma proteins, rise in investment in innovation, and increase in prevalence of rare diseases across the world are key factors that are projected to propel the global plasma fractionation market. The plasma fractionation industry has been investing in research and development of new plasma proteins therapies (e.g.: Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients. For instance, in March 2016, Grifols announced that it would invest US$ 360 Mn to expand its production capabilities for plasma-derived therapies. The investment is expected to increase the capacity of plasma fractionation and purification of several proteins. Moreover, rise in investments in innovation leads to technological advancements in efficient and cost-effective procedures for fractionating proteins from plasma, which in turn boost the plasma fractionation market. However, rising market penetration by recombinant factors and stringent regulations and reimbursement issues are major factors restraining the global plasma fractionation market.
The global plasma fractionation market has been segmented based on product type, application, end-user and region. In terms of product type, the global plasma fractionation market has been classified into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The immunoglobulin segment has been further sub-segmented into intravenous immunoglobulin and subcutaneous immunoglobulin. The coagulation factor concentrates segment factor VIII, factor IX, factor XIII, prothrombin complex concentrate, Von Willebrand factor, and fibrinogen concentrates. In terms of application, the global plasma fractionation market has been classified into neurology, immunology, hematology, critical care, pulmonology, and other applications. In terms of end-user, the global market has been segregated into hospitals and clinics, clinical research laboratories, and academic institutes. In terms of region, the global plasma fractionation market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Based on product type, the immunoglobulin segment dominates the global plasma fractionation market. The segment dominates the market, owing to the rise prevalence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. According to the Immune Deficiency Foundation (IDF), approximately 83 people per 100,000 in the U.S. suffer from primary immunodeficiency, and there are more than 5 million undiagnosed cases in the U.S. alone each year. Hence, these factors boost the rate of adoption of immunoglobulins, which in turn boosts the market. The albumin segment is also anticipated to expand at a steady pace during the forecast period. Wide applications of human albumin as a drug formulation agent, vaccine ingredient, sealant in surgeries, and coating for medical devices and equipment are likely to propel the segment in the next few years.
Based on application, the neurology segment dominates the global plasma fractionation market. Rise in number of neurological disorders augments the segment. World Health Organization data suggest that neurological and psychiatric disorders are an important and growing cause of morbidity. The magnitude and burden of mental, neurological, and behavioral disorders is huge, affecting more than 450 million people globally per year.
Based on end-user, the hospital and clinics segment dominates the global plasma fractionation market. Hospitals are witnessing robust expansion, propelled by joint ventures, acquisitions, and provision of one-stop-shop services under one roof for various medical needs.
In terms of region, North America and Europe accounted for a combined market share of 60% in 2017. High prevalence of infectious diseases such as cholera, influenza, and syphilis in North America fuelled the demand for utilization of plasma fractionation. Likewise, Europe accounted for a prominent share, and followed North America in terms of share, of the total global market, due to the presence of a large geriatric population that is more prone to infections. Asia Pacific is regarded as an emerging market for plasma fractionation owing to the presence of large patient population, poor sanitization, and low awareness about plasma fractionation products among the people in the region.
Major players operating in the global plasma fractionation market include CSL Limited, Shire plc, Sanquin, Biotest AG., GRIFOLS, Baxter International Inc., Kedrion, Octapharma and China Biologic Products Holdings, Inc. These players adopt organic and in-organic growth strategies in order to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.
The global plasma fractionation market has been segmented as follows:
|
by Product Type |
|
|
by Application |
|
|
by End-user |
|
|
by Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Plasma Fractionation Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Plasma Fractionation Market Analysis and Forecast, 2016–2026
5. Market Outlook
5.1. Regional Distribution of Fractionation Plants
5.2. Regional Distribution of Fractionation Throughput
5.3. Worldwide IVIG Unit Sales by Region
5.4. Worldwide Albumin Unit Sales by Region
5.5. Plasma Proteins and their Clinical Significance
5.6. Value Chain Analysis
6. Global Plasma Fractionation Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
6.3.1. Immunoglobulin
6.3.1.1. Intravenous Immunoglobulin
6.3.1.2. Subcutaneous Immunoglobulin
6.3.2. Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Factor XIII
6.3.2.4. Prothrombin Complex Concentrates
6.3.2.5. Von Willebrand Factor (VWF)
6.3.2.6. Fibrinogen Concentrates
6.3.3. Albumin
6.3.4. Protease Inhibitors
6.3.5. Other Plasma Products
6.6. Global Plasma Fractionation Market Attractiveness, by Product Type
7. Global Plasma Fractionation Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Global Plasma Fractionation Market Value Forecast, by Application, 2016–2026
7.2.1. Neurology
7.2.2. Immunology
7.2.3. Hematology
7.2.4. Critical Care
7.2.5. Pulmonology
7.2.6. Other Applications
7.7. Global Plasma Fractionation Market Attractiveness, by Product
8. Global Plasma Fractionation Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Global Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
8.2.1. Hospitals and Clinics
8.2.2. Clinical Research Laboratories
8.2.3. Academic Institutes
9. Global Plasma Fractionation Market Analysis and Forecast, by Region
9.1. Global Market Scenario
9.2. Global Plasma Fractionation Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Plasma Fractionation Market Attractiveness, by Region
10. North America Plasma Fractionation Market Analysis and Forecast
10.1. Introduction
10.2. North America Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
10.2.1. Immunoglobulin
10.2.1.1. Intravenous Immunoglobulin
10.2.1.2. Subcutaneous Immunoglobulin
10.2.2. Coagulation Factor Concentrates
10.2.2.1. Factor VIII
10.2.2.2. Factor IX
10.2.2.3. Factor XIII
10.2.2.4. Prothrombin Complex Concentrates
10.2.2.5. Von Willebrand Factor (VWF)
10.2.2.6. Fibrinogen Concentrates
10.2.3. Albumin
10.2.4. Protease Inhibitors
10.2.5. Other Plasma Products
10.3. North America Plasma Fractionation Market Value Forecast, by Application, 2016–2026
10.3.1. Neurology
10.3.2. Immunology
10.3.3. Hematology
10.3.4. Critical Care
10.3.5. Pulmonology
10.3.6. Other Applications
10.4. North America Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
10.4.1. Hospitals and Clinics
10.4.2. Clinical Research Laboratories
10.4.3. Academic Institutes
10.5. North America Plasma Fractionation Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Plasma Fractionation Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. Country
11. Europe Plasma Fractionation Market Analysis and Forecast
11.1. Introduction
11.2. Europe Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
11.2.1. Immunoglobulin
11.2.1.1. Intravenous Immunoglobulin
11.2.1.2. Subcutaneous Immunoglobulin
11.2.2. Coagulation Factor Concentrates
11.2.2.1. Factor VIII
11.2.2.2. Factor IX
11.2.2.3. Factor XIII
11.2.2.4. Prothrombin Complex Concentrates
11.2.2.5. Von Willebrand Factor (VWF)
11.2.2.6. Fibrinogen Concentrates
11.2.3. Albumin
11.2.4. Protease Inhibitors
11.2.5. Other Plasma Products
11.3. Europe Plasma Fractionation Market Value Forecast, by Application, 2016–2026
11.3.1. Neurology
11.3.2. Immunology
11.3.3. Hematology
11.3.4. Critical Care
11.3.5. Pulmonology
11.3.6. Other Applications
11.4. Europe Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
10.4.1. Hospitals and Clinics
10.4.2. Clinical Research Laboratories
10.4.3. Academic Institutes
11.5. Europe Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Plasma Fractionation Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By End-user
11.6.4. Country
12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
12.2.1. Immunoglobulin
12.2.1.1. Intravenous Immunoglobulin
12.2.1.2. Subcutaneous Immunoglobulin
12.2.2. Coagulation Factor Concentrates
12.2.2.1. Factor VIII
12.2.2.2. Factor IX
12.2.2.3. Factor XIII
12.2.2.4. Prothrombin Complex Concentrates
12.2.2.5. Von Willebrand Factor (VWF)
12.2.2.6. Fibrinogen Concentrates
12.2.3. Albumin
12.2.4. Protease Inhibitors
12.2.5. Other Plasma Products
12.3. Asia Pacific Plasma Fractionation Market Value Forecast, by Application, 2016–2026
12.3.1. Neurology
12.3.2. Immunology
12.3.3. Hematology
12.3.4. Critical Care
12.3.5. Pulmonology
12.3.6. Other Applications
12.4. Asia Pacific Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
12.4.1. Hospitals and Clinics
12.4.2. Clinical Research Laboratories
12.4.3. Academic Institutes
12.5. Asia Pacific Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Plasma Fractionation Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. Country
13. Latin America Plasma Fractionation Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
13.2.1. Immunoglobulin
13.2.1.1. Intravenous Immunoglobulin
13.2.1.2. Subcutaneous Immunoglobulin
13.2.2. Coagulation Factor Concentrates
13.2.2.1. Factor VIII
13.2.2.2. Factor IX
13.2.2.3. Factor XIII
13.2.2.4. Prothrombin Complex Concentrates
13.2.2.5. Von Willebrand Factor (VWF)
13.2.2.6. Fibrinogen Concentrates
13.2.3. Albumin
13.2.4. Protease Inhibitors
13.2.5. Other Plasma Products
13.3. Latin America Plasma Fractionation Market Value Forecast, by Application, 2016–2026
13.3.1. Neurology
13.3.2. Immunology
13.3.3. Hematology
13.3.4. Critical Care
13.3.5. Pulmonology
13.3.6. Other Applications
13.4. Latin America Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
13.4.1. Hospitals and Clinics
13.4.2. Clinical Research Laboratories
13.4.3. Academic Institutes
13.5. Latin America Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Plasma Fractionation Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. Country
14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
14.2.1. Immunoglobulin
14.2.1.1. Intravenous Immunoglobulin
14.2.1.2. Subcutaneous Immunoglobulin
14.2.2. Coagulation Factor Concentrates
14.2.2.1. Factor VIII
14.2.2.2. Factor IX
14.2.2.3. Factor XIII
14.2.2.4. Prothrombin Complex Concentrates
14.2.2.5. Von Willebrand Factor (VWF)
14.2.2.6. Fibrinogen Concentrates
14.2.3. Albumin
14.2.4. Protease Inhibitors
14.2.5. Other Plasma Products
14.3. Middle East & Africa Plasma Fractionation Market Value Forecast, by Application, 2016–2026
14.3.1. Neurology
14.3.2. Immunology
14.3.3. Hematology
14.3.4. Critical Care
14.3.5. Pulmonology
14.3.6. Other Applications
14.4. Middle East & Africa Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
14.4.1. Hospitals and Clinics
14.4.2. Clinical Research Laboratories
14.4.3. Academic Institutes
14.5. Middle East & Africa Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Plasma Fractionation Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By End-user
14.6.4. Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. CSL Limited
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Shire plc
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Sanquin
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Biotest AG.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. GRIFOLS
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Baxter International Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Kedrion
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Octapharma
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. China Biologic Products Holdings, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
List of Tables
Table 01: Plasma Proteins for Clinical Use
Table 02: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
Table 03: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
Table 04: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, Coagulation Factor Concentrates, 2016–2026
Table 05: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
Table 06: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 07: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
Table 08 : North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
Table 10: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
Table 11: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
Table 12: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
Table 13: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 14: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
Table 16: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
Table 17: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
Table 18: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
Table 19: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 20: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
Table 22: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
Table 23: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
Table 24: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
Table 25: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 26: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
Table 28: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
Table 29: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
Table 30: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
Table 31: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 32: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 33: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
Table 34: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
Table 35: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
Table 36: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
Table 37: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
List of Figures
Figure 01: Global Plasma Fractionation Market Size (US$ Mn) and Distribution (%), by Region, 2018 and 2026
Figure 02: Global Plasma Fractionation Market Value Share, by Product Type (2017)
Figure 03: Global Plasma Fractionation Market Value Share, by Application (2017)
Figure 04: Global Plasma Fractionation Market Value Share, by Region (2017)
Figure 05: Opportunity Map, 2017
Figure 06: Plasma Fractionation Market Size (US$ Mn) Forecast, 2018–2026
Figure 07: Regional Distribution of Fractionation Plants
Figure 08: Regional Distribution of Fractionation Throughput
Figure 09: Worldwide IVIG Unit Sales by Region
Figure 10: Worldwide Albumin Unit Sales by Region
Figure 11: Global Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
Figure 12: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Immunoglobulin
Figure 13: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Coagulation Factor Concentrates
Figure 14: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Albumin
Figure 15: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Protease Inhibitors
Figure 16: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Plasma Products
Figure 17: Global Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
Figure 18: Global Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
Figure 19: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Neurology
Figure 20: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Immunology
Figure 21: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hematology
Figure 22: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Critical Care
Figure23: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Pulmonology
Figure 24: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Applications
Figure 25: Global Plasma Fractionation Market Attractiveness, by Application, 2018–2026
Figure 26: Global Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
Figure 27: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics
Figure28: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Clinical Research Laboratories
Figure 29: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic Institutes
Figure 30: Global Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
Figure 31: Global Plasma Fractionation Market Value Share (%), by Region, 2018 and 2026
Figure 32: Global Plasma Fractionation Market Attractiveness, by Region, 2018–2026
Figure 33: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 34: North America Plasma Fractionation Market Value Share (%), by Country, 2018 and 2026
Figure 35: North America Plasma Fractionation Market Attractiveness, by Country, 2018–2026
Figure 36: North America Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
Figure 37: North America Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
Figure 38: North America Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
Figure 39: North America Plasma Fractionation Market Attractiveness, by Application, 2018–2026
Figure 40: North America Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
Figure 41: North America Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
Figure 42: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 43: Europe Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 44: Europe Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 45: Europe Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
Figure 46: Europe Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
Figure 47: Europe Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
Figure 48: Europe Plasma Fractionation Market Attractiveness, by Application, 2018–2026
Figure 49: Europe Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
Figure 50: Europe Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
Figure 51: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 52: Asia Pacific Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 53: Asia Pacific Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 54: Asia Pacific Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
Figure 55: Asia Pacific Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
Figure 56: Asia Pacific Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
Figure 57: Asia Pacific Plasma Fractionation Market Attractiveness, by Application, 2018–2026
Figure 58: Asia Pacific Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
Figure 59: Asia Pacific Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
Figure 60: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 61: Latin America Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 62: Latin America Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 63: Latin America Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
Figure 64: Latin America Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
Figure 65: Latin America Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
Figure 66: Latin America Plasma Fractionation Market Attractiveness, by Application, 2018–2026
Figure 67: Latin America Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
Figure 68: Latin America Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
Figure 69: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure70: Middle East & Africa Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 71: Middle East & Africa Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 72: Middle East & Africa Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
Figure 73: Middle East & Africa Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
Figure 74: Middle East & Africa Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
Figure 75: Middle East & Africa Plasma Fractionation Market Attractiveness, by Application, 2018–2026
Figure 76: Middle East & Africa Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
Figure 77: Middle East & Africa Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes